Insulet Q2 2026 earnings: Omnipod drives 23.5% revenue growth

Insulet (NASDAQ: PODD) reported Q2 2026 revenue of $801.7 million, up 23.5% from $649.1 million, while diluted EPS increased to $1.37 from $0.32. Omnipod drove the revenue gain, particularly in international markets, but voluntary medical device correction costs weighed on GAAP margins even as adjusted profitability improved. For the first six months of 2026, free cash flow remained positive but declined year over year.

Core earnings data

Revenue growth came almost entirely from Omnipod. Total Omnipod revenue increased by $156.9 million, more than offsetting a $4.4 million decline in Drug Delivery revenue.

Net income grew much faster than operating income partly because the prior-year quarter included an $84.4 million loss on extinguishment of debt. Adjusted net income, which removes that prior-period item and other specified adjustments, rose 37.4%.

Insulet’s adjusted measures exclude items including medical device correction costs, executive transition costs and, when applicable, losses on debt extinguishment and investments.

Business and segment performance

International Omnipod remained the fastest-growing business, increasing 35.5% as reported and 32.9% in constant currency. U.S. Omnipod generated the larger dollar increase, while Drug Delivery continued to contract.

During the quarter, Insulet launched Omnipod 5 and Omnipod Discover in Spain, its 26th Omnipod market and the 20th country offering Omnipod 5. The company also introduced a next-generation algorithm and expanded Omnipod 5 compatibility to Abbott’s FreeStyle Libre 3 Plus. Clinical presentations included STRIVE results supporting Omnipod 6 and an EVOLUTION feasibility study of fully closed-loop technology for people with type 2 diabetes.

Medical device correction costs widen the gap between GAAP and adjusted margins

The main profitability issue was the contrast between reported and adjusted results. GAAP operating margin fell 250 basis points to 16.2%, while adjusted operating margin rose by more than 140 basis points to 19.3%.

Insulet recorded $21.9 million of estimated warranty costs at the gross-profit level related to voluntary medical device corrections issued in March and May 2026. Total operating-income adjustments associated with those corrections were $25.0 million. After the adjustments, gross profit was $584.4 million with a 72.9% margin, compared with the reported 70.2% margin.

Operating expenses also increased. Research and development expense rose to $88.1 million from $73.4 million, while selling, general and administrative expense increased to $344.8 million from $257.7 million. The latter grew faster than revenue and contributed to the pressure on GAAP operating leverage.

Cash flow and balance sheet

The company reported cash flow only for the six-month period, so these figures should not be treated as standalone Q2 results. First-half operating cash flow declined, while capital expenditures increased, reducing free cash flow by approximately 37% year over year.

Cash and cash equivalents stood at $534.9 million on June 30, down from $716.1 million at the end of 2025. Accounts receivable increased to $588.7 million from $516.9 million, and inventories rose to $484.8 million from $452.6 million. Total debt was approximately $948.4 million, little changed from approximately $949.2 million at year-end.

Management’s perspective

CEO Ashley McEvoy emphasized broad-based Omnipod growth, adjusted margin expansion and positive free cash flow. She also said Insulet was applying lessons learned while scaling its type 2 diabetes business and remained focused on improving execution and supporting durable, profitable growth.

Recent insider transactions

The provided six-month insider summary recorded 70,228 shares under purchases across 29 transactions and 418 shares under sales in one transaction, resulting in net purchases of 69,810 shares. Among the records identified specifically as purchases or sales, three director transactions were reported on June 3, 2026.

More recent entries included director stock awards, which are compensation grants and should be distinguished from purchases and sales. The reported transactions do not by themselves establish insiders’ views on Insulet’s outlook.

Risks investors need to watch

• Type 2 diabetes execution: Management said it was updating its approach based on lessons from scaling in type 2 diabetes. Converting those lessons into sustained customer adoption and revenue growth remains an execution issue.
• Medical device correction costs: The March and May 2026 corrections generated $25.0 million of Q2 operating adjustments. Additional related costs or operating effects would continue to create differences between GAAP and adjusted profitability.
• Lower cash conversion: First-half operating cash flow declined while capital expenditures increased, reducing free cash flow despite higher earnings.
• Dependence on Omnipod: Omnipod generated about 99% of Q2 revenue, while Drug Delivery revenue fell 43.1%. This leaves overall performance highly dependent on continued Omnipod adoption.

Summary

Insulet’s second-quarter growth remained centered on Omnipod, with international markets expanding faster than the U.S. business. Adjusted earnings and margins improved, but medical device correction costs and faster SG&A growth pressured GAAP operating margin. The next areas to monitor are execution in type 2 diabetes, the financial impact of the device corrections and whether cash flow improves as product development and geographic expansion continue.